{"id":"NCT01389596","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years","officialTitle":"A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS ADJUNCTIVE THERAPY IN CHILDREN 4 -16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09-27","primaryCompletion":"2016-08-10","completion":"2016-08-10","firstPosted":"2011-07-08","resultsPosted":"2017-03-21","lastUpdate":"2021-01-20"},"enrollment":295,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy, Partial Seizures"],"interventions":[{"type":"DRUG","name":"Pregabalin add-on therapy","otherNames":[]},{"type":"DRUG","name":"Pregabalin add-on therapy","otherNames":[]},{"type":"DRUG","name":"Pregabalin add-on therapy","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Pregabalin Level 1 (max 150 mg/day)","type":"EXPERIMENTAL"},{"label":"Pregabalin Level 2 (max 600 mg day)","type":"EXPERIMENTAL"}],"summary":"Study A0081041 is a double blind, placebo controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of two dose levels of pregabalin administered in equally divided daily doses, in either capsule or oral liquid formulation, as adjunctive therapy in pediatric subjects 4 to 16 years of age with partial onset seizures.","primaryOutcome":{"measure":"Log-Transformed 28-Day Seizure Rate For All Partial Onset Seizures During Baseline Phase","timeFrame":"Baseline phase (up to 8 weeks prior to treatment phase [Day 1])","effectByArm":[{"arm":"Pregabalin: 2.5 mg/kg/Day or 3.5 mg/kg/Day","deltaMin":3.27,"sd":1.215},{"arm":"Pregabalin: 10 mg/kg/Day or 14 mg/kg/Day","deltaMin":3.19,"sd":1.269},{"arm":"Placebo","deltaMin":3.18,"sd":1.302}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":86,"countries":["United States","Belgium","Bulgaria","Czechia","France","Greece","Hungary","Israel","Italy","Malaysia","Philippines","Poland","Romania","Serbia","Singapore","South Korea","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["30688135"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081041&StudyName=A%20Study%20of%20the%20Efficacy%20and%20Safety%20of%20Pregabalin%20as%20Add-On%20Therapy%20for%20Partial%20Onset%20Seizures%20in%20Children%20Ages%204-16%20Years"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":104},"commonTop":["Somnolence","Upper respiratory tract infection","Pyrexia","Nasopharyngitis","Weight increased"]}}